Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.
https://www.soleburytrout.com/lifesciences
Gerben Moolhuizen, ISA Pharmaceuticals - Part of the NameTag Series
Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. Prior to ISA Pharmaceuticals, he worked at OctoPlus, where his most recent role was General Manager. He has been closely involved in the company´s fundraising activities, IPO, and the acquisition by Dr. Reddy’s and has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy’s R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming, where he held various roles in business development and product development and was also involved in the company´s IPO in 1998. He holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam.